Literature DB >> 31748695

The deubiquitinase USP10 regulates KLF4 stability and suppresses lung tumorigenesis.

Xingyun Wang1,2, Shilin Xia3, Hongchang Li4, Xiang Wang1, Chaonan Li4, Yulin Chao1, Lingqiang Zhang5, Chuanchun Han6.   

Abstract

Krüppel-like factor 4 (KLF4), a key transcription factor, acts as a multifunctional player involved in the progression of numerous aggressive cancers. The proteasome-dependent pathway is one of the main modalities in controlling KLF4 abundance at a posttranslational level. Although some of the ubiquitin ligases have been identified, the deubiquitinases of KLF4 and the regulatory function remain unexplored. Here, by screening ubiquitin-specific proteases that may interact with KLF4, we found ubiquitin-specific peptidase 10 (USP10) as a deubiquitinating enzyme for KLF4. Forced expression of USP10 remarkably increases KLF4 protein level by blocking the latter degradation, whereas the depletion of USP10 promotes KLF4 degradation and thus enhances tumorigenesis. Loss of USP10 in mice downregulates KLF4 expression and accelerates KrasG12D-driven lung adenocarcinoma initiation and progression. In addition, our data revealed that KLF4 can facilitate the transcription of tumor suppressor TIMP3 by directly binding to the TIMP3 promoter. Clinically, reduction of USP10 expression, concomitant with decreased KLF4 and TIMP3 abundance in carcinoma tissue, predicts poor prognosis of lung cancer patient. Taken together, our results demonstrate that USP10 is a critical regulator of KLF4, pinpointing USP10-KLF4-TIMP3 axis as a promising therapeutic target in lung cancer.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31748695      PMCID: PMC7244734          DOI: 10.1038/s41418-019-0458-7

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  48 in total

Review 1.  The ubiquitin system.

Authors:  A Hershko; A Ciechanover
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

Review 2.  From Discovery to Bedside: Targeting the Ubiquitin System.

Authors:  Ingrid E Wertz; Xiaojing Wang
Journal:  Cell Chem Biol       Date:  2018-12-13       Impact factor: 8.116

Review 3.  RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis.

Authors:  Stanley Lipkowitz; Allan M Weissman
Journal:  Nat Rev Cancer       Date:  2011-08-24       Impact factor: 60.716

4.  Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

Authors:  Ramaswamy Govindan; Nathan Page; Daniel Morgensztern; William Read; Ryan Tierney; Anna Vlahiotis; Edward L Spitznagel; Jay Piccirillo
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

Review 5.  Non-small-cell lung cancer.

Authors:  Cesare Gridelli; Antonio Rossi; David P Carbone; Juliana Guarize; Niki Karachaliou; Tony Mok; Francesco Petrella; Lorenzo Spaggiari; Rafael Rosell
Journal:  Nat Rev Dis Primers       Date:  2015-05-21       Impact factor: 52.329

Review 6.  Targeting the ubiquitin system in cancer therapy.

Authors:  Daniela Hoeller; Ivan Dikic
Journal:  Nature       Date:  2009-03-26       Impact factor: 49.962

Review 7.  New pathologic classification of lung cancer: relevance for clinical practice and clinical trials.

Authors:  William D Travis; Elisabeth Brambilla; Gregory J Riely
Journal:  J Clin Oncol       Date:  2013-02-11       Impact factor: 44.544

Review 8.  Ubiquitin ligases in oncogenic transformation and cancer therapy.

Authors:  Daniela Senft; Jianfei Qi; Ze'ev A Ronai
Journal:  Nat Rev Cancer       Date:  2017-12-15       Impact factor: 60.716

9.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

Review 10.  Deubiquitylating enzymes and drug discovery: emerging opportunities.

Authors:  Jeanine A Harrigan; Xavier Jacq; Niall M Martin; Stephen P Jackson
Journal:  Nat Rev Drug Discov       Date:  2017-09-29       Impact factor: 84.694

View more
  29 in total

1.  Dissenting degradation: Deubiquitinases in cell cycle and cancer.

Authors:  Thomas Bonacci; Michael J Emanuele
Journal:  Semin Cancer Biol       Date:  2020-03-20       Impact factor: 15.707

Review 2.  Research Progress of DUB Enzyme in Hepatocellular Carcinoma.

Authors:  Jie Zhao; Jinhui Guo; Yanan Wang; Qiancheng Ma; Yu Shi; Feng Cheng; Qiliang Lu; Wen Fu; Guangxiong Ouyang; Ji Zhang; Qiuran Xu; Xiaoge Hu
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

Review 3.  NUCB2: roles in physiology and pathology.

Authors:  Qing Zhou; Ying Liu; Ranran Feng; Wenling Zhang
Journal:  J Physiol Biochem       Date:  2022-06-09       Impact factor: 5.080

4.  The Prognostic Value and Immune Infiltration of USP10 in Pan-Cancer: A Potential Therapeutic Target.

Authors:  Dacheng Gao; Zhiwen Zhang; Rui Xu; Ziyang He; Fangyi Li; Yan Hu; Hui Chen; Jiawei Lu; Xingguo Cao; Yali Liu; Zengguang Xu
Journal:  Front Oncol       Date:  2022-03-31       Impact factor: 6.244

5.  Potential Prognostic Biomarkers of Lung Adenocarcinoma Based on Bioinformatic Analysis.

Authors:  Jili Hou; Cheng Yao
Journal:  Biomed Res Int       Date:  2021-01-14       Impact factor: 3.411

Review 6.  Recent Discoveries on the Involvement of Krüppel-Like Factor 4 in the Most Common Cancer Types.

Authors:  Agnieszka Taracha-Wisniewska; Grzegorz Kotarba; Sebastian Dworkin; Tomasz Wilanowski
Journal:  Int J Mol Sci       Date:  2020-11-22       Impact factor: 5.923

7.  ITIH5, a p53-responsive gene, inhibits the growth and metastasis of melanoma cells by downregulating the transcriptional activity of KLF4.

Authors:  Jia Liu; Feng Cao; Xiaojie Li; Li Zhang; Zhengrong Liu; Xiaodong Li; Jingrong Lin; Chuanchun Han
Journal:  Cell Death Dis       Date:  2021-05-02       Impact factor: 8.469

8.  Deubiquitinase USP35 modulates ferroptosis in lung cancer via targeting ferroportin.

Authors:  Zheng Tang; Wanli Jiang; Ming Mao; Jinping Zhao; Jiakuan Chen; Nitao Cheng
Journal:  Clin Transl Med       Date:  2021-04

9.  Identification of Prognostic Signature and Gliclazide as Candidate Drugs in Lung Adenocarcinoma.

Authors:  Yang Cheng; Kezuo Hou; Yizhe Wang; Yang Chen; Xueying Zheng; Jianfei Qi; Bowen Yang; Shiying Tang; Xu Han; Dongyao Shi; Ximing Wang; Yunpeng Liu; Xuejun Hu; Xiaofang Che
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

10.  Development and Validation of Autophagy-Related Gene Signature and Nomogram for Predicting Survival in Oral Squamous Cell Carcinoma.

Authors:  Chen Hou; Hongshi Cai; Yue Zhu; Shuojin Huang; Fan Song; Jinsong Hou
Journal:  Front Oncol       Date:  2020-10-16       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.